Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ANI Pharmaceuticals, Inc. - Common Stock (NQ:ANIP)

93.85 +1.90 (+2.07%)
Streaming Delayed Price Updated: 11:42 AM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ANI Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
ANI Pharmaceuticals Announces the FDA Approval and Launch of Levocarnitine Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals's Return On Capital Employed Overview
 
Via Benzinga
ANI Pharmaceuticals Announces the FDA Approval and Launch of Fluoxetine Oral Solution USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Via Benzinga
ANI Pharmaceuticals Announces the FDA Approval and Launch of Trimethoprim Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals: Q2 Earnings Insights
  ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q2 earnings results on Monday, August 8, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
ANI Pharmaceuticals: Q1 Earnings Insights
ANI Pharmaceuticals (NASDAQ:ANIP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:50 AM. Here's what investors need to know about the announcement. 
Via Benzinga
ANI Pharmaceuticals Reports Third Quarter 2022 Financial Results; Reports Record Net Revenues
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals to Discuss Third Quarter 2022 Financial Results on November 9, 2022, at 8:00 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Appoints Krista Davis as Chief Human Resources Officer
From ANI Pharmaceuticals, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 7, 2022
Upgrades 
Via Benzinga
ANI Pharmaceuticals to Present at the H.C. Wainwright 24th Annual Global Investment Conference
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the Launch of Prochlorperazine Maleate Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
  
Via Benzinga
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Dexamethasone Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Reports Second Quarter 2022 Financial Results; Reports Record Net Revenues and Raises Full-Year 2022 Net Revenue Guidance for Purified Cortrophin® Gel
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the Launch of Acebutolol Hydrochloride Capsules USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Acquires ANDAs from Oakrum Pharma, LLC
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals to Discuss Second Quarter 2022 Financial Results on August 8, 2022, at 8:00 a.m. ET
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Appoints Meredith W. Cook as SVP, General Counsel and Corporate Secretary
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces FDA Approval and Imminent Launch of Clorazepate Dipotassium Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals's Return On Capital Employed Overview
According to data from Benzinga Pro, during Q1, ANI Pharmaceuticals's (NASDAQ:ANIP) reported sales totaled $64.48 million. Despite a 16.6% increase in earnings, the company posted a loss of $20.13... 
Via Benzinga
ANI Pharmaceuticals Announces Consolidation of Manufacturing Network, Capturing Operational Synergies Post Novitium Acquisition
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the FDA Approval and Imminent Launch of Fludrocortisone Acetate Tablets USP
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals to Present at Upcoming Healthcare Investor Conferences
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Reports First Quarter 2022 Results; Provides Purified Cortrophin® Gel Net Revenue Guidance and Full-Year 2022 Total Company Net Revenue Guidance of $295 Million to $315 Million
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Q1 2022 Earnings Conference Call On May 10, 2022 At 08:30 AM ET
ANI Pharmaceuticals (NASDAQ:ANIP) will host a conference call at 08:30 AM ET on May 10, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
ANI Pharmaceuticals to Discuss First Quarter 2022 Financial Results on May 10, 2022
From ANI Pharmaceuticals, Inc.
Via Business Wire
ANI Pharmaceuticals Announces the Launch of Misoprostol Tablets
From ANI Pharmaceuticals, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.